<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935840</url>
  </required_header>
  <id_info>
    <org_study_id>2020_FBE_04</org_study_id>
    <nct_id>NCT04935840</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of FertyBiotic Pregnancy in the Metabolic Profile in Pregnant Women</brief_title>
  <official_title>Clinical Study to Evaluate the Effect of a Food Supplement With Probiotics on the Metabolic Profile of Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fertypharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fertypharm</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is determine the effect of a food supplement with probiotics on&#xD;
      metabolic profile and weight gain in pregnant women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study, all patients meeting the inclusion/exclusion criteria&#xD;
      and giving written informed consent will be randomized in a double-blind manner in a ratio&#xD;
      1:1 to receive the food supplementation associated with probiotics or placebo (folic acid)&#xD;
      once daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">September 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose homeostasis</measure>
    <time_frame>30-32 weeks gestation</time_frame>
    <description>Glucose homeostasis status will be evaluated by measuring fasting glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin levels</measure>
    <time_frame>30-32 weeks gestation</time_frame>
    <description>Insulin levels status will be evaluated by measuring fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>30-32 weeks gestation</time_frame>
    <description>Insulin resistance will be evaluated by measuring HOMA IR and QUICKI index (fasting glucose and fasting insulin combination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight gain</measure>
    <time_frame>30-32 weeks gestation</time_frame>
    <description>Weight will be evaluated weighting the subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid concentration</measure>
    <time_frame>30-32 weeks gestation</time_frame>
    <description>Lipid concentration will be evaluated by measuring fasting total colesterol, LDL, HDL and triglyceride</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>FertyBiotic Pregnancy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received FertyBiotic Pregnancy one capsule a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received 400 mcg of folic acid once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FertyBiotic Pregnancy</intervention_name>
    <description>DHA, folic acid, Iodine, iron, Lactobacillus rhamnosus, Lactobacillus reuterii, magnesium, zinc, vitamin D3, Vitamin C, Vitamin E, Group B vitamins and Biotin</description>
    <arm_group_label>FertyBiotic Pregnancy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>400 mcg of folic acid</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Age: &gt; 35 years old&#xD;
&#xD;
          -  BMI &gt; 25&#xD;
&#xD;
          -  Women who have signed the informed consent to participate in the study.&#xD;
&#xD;
          -  No intention to change their routine physical activity or usual dietary intakes&#xD;
             throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &gt; 14 weeks' gestation&#xD;
&#xD;
          -  Taking food supplements or probiotics&#xD;
&#xD;
          -  History or current pathology that influence in the study&#xD;
&#xD;
          -  With major fetal abnormalities&#xD;
&#xD;
          -  Had used continuous antibiotic therapy for at least 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnancy</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giron√©s Roberto</last_name>
      <phone>962339300</phone>
    </contact>
    <contact_backup>
      <last_name>Victoria Gomis</last_name>
      <phone>962339300</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

